Shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Free Report) gapped down before the market opened on Thursday . The stock had previously closed at $9.37, but opened at $9.07. Ginkgo Bioworks shares last traded at $9.15, with a volume of 72,109 shares.
Analyst Upgrades and Downgrades
Separately, TD Cowen upped their target price on shares of Ginkgo Bioworks from $3.00 to $10.00 and gave the company a “buy” rating in a research note on Friday, September 20th. Three investment analysts have rated the stock with a sell rating, one has assigned a hold rating and one has given a buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $4.58.
Check Out Our Latest Stock Analysis on Ginkgo Bioworks
Ginkgo Bioworks Stock Performance
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently modified their holdings of the business. AQR Capital Management LLC bought a new position in Ginkgo Bioworks in the second quarter worth about $3,391,000. Monaco Asset Management SAM bought a new stake in shares of Ginkgo Bioworks in the 2nd quarter worth approximately $3,276,000. Renaissance Technologies LLC acquired a new position in Ginkgo Bioworks during the 2nd quarter valued at approximately $2,128,000. XTX Topco Ltd bought a new position in Ginkgo Bioworks during the 2nd quarter worth $312,000. Finally, Mackenzie Financial Corp acquired a new stake in Ginkgo Bioworks in the second quarter worth $251,000. 78.63% of the stock is owned by institutional investors and hedge funds.
Ginkgo Bioworks Company Profile
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
Recommended Stories
- Five stocks we like better than Ginkgo Bioworks
- 5 Top Rated Dividend Stocks to Consider
- S&P 500 ETFs: Expense Ratios That Can Boost Your Long-Term Gains
- Do ETFs Pay Dividends? What You Need to Know
- How AI Implementation Could Help MongoDB Roar Back in 2025
- Compound Interest and Why It Matters When Investing
- Hedge Funds Boost Oil Positions: Is a Major Rally on the Horizon?
Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.